Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Amna Ibrahim(Beni-Suef University), Richard Pazdur(United States Food and Drug Administration), John Leighton, Nancy S. Scher, Jogarao Gobburu(University of Maryland, Baltimore), Atiqur Rahman(Jamia Millia Islamia), Debra Vause, Ning Li(Shenyang Pharmaceutical University), Gang Chen(Tongji Hospital), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Brian Booth, Yung Hsieh, Rebecca Wood, Grant Williams
PubMed
July 1, 2003
Cited by 198

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861